Cambiogenplasmid

Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF). Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF. It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.